Hope for people with rare genetic disorderーNHK WORLD-JAPAN NEWS

Key Concepts:

• Gene Therapy
• GLUT1 Deficiency Syndrome (Glute One)
• Glucose Transporter 1 Deficiency Syndrome
• Intractable Genetic Disorder
• Clinical Trial
• Viral Vector
• Dietary Therapy (Ketogenic Diet)
• Pharmaceutical Development
• Government Support for Medical Research

Breakthrough Gene Therapy Trial for GLUT1 Deficiency Syndrome in Japan

A significant development in the treatment of rare genetic disorders is underway at a university hospital in Tochigi Prefecture, north of Tokyo. The hospital has initiated a gene therapy clinical trial for patients diagnosed with GLUT1 deficiency syndrome, a debilitating condition characterized by seizures and physical/mental disabilities. This trial is particularly noteworthy as it highlights progress in gene therapy research in Japan, an area perceived to be lagging behind Western countries.

Understanding GLUT1 Deficiency Syndrome

GLUT1 deficiency syndrome, also known as glucose transporter 1 deficiency syndrome, is a rare genetic neurological disorder. The core issue stems from an abnormality in the gene responsible for producing glucose transporter 1 (GLUT1). This deficiency leads to insufficient glucose supply to the brain, a critical energy source for neurological function. The lack of energy in the brain manifests as a range of severe symptoms, including frequent seizures, physical impairments, and cognitive disabilities.

The Gene Therapy Approach

The gene therapy being tested involves the injection of an artificially produced, specialized virus directly into the brain. This virus acts as a vector, designed to deliver genetic material that can prompt the impaired gene to function correctly. The ultimate goal is to improve the patient's symptoms by restoring proper glucose transport to the brain.

Early Observations from the Clinical Trial

Kane Maru Yuya, a 27-year-old patient with GLUT1 deficiency, is participating in this clinical trial. He expressed his strong desire for such a treatment, stating, "Saying no to a clinical trial was not an option. I'd always hoped there would be an opportunity to undergo such therapy."

Two months post-injection, initial assessments of Kane Maru's progress were discussed by the medical team. While there has been no observed change in the frequency of his seizures, improvements in his physical and emotional condition have been noted. A comprehensive official evaluation is scheduled for six months after the injection.

The Current Standard of Care: Dietary Therapy

For GLUT1 deficiency patients, the only available symptomatic treatment is a strict dietary therapy. This regimen, often referred to as a ketogenic diet, involves a high-fat and low-carbohydrate intake. The purpose of this diet is to encourage the body to produce ketones, which can serve as an alternative energy source for the brain when glucose is insufficient.

Fura Minodi, a patient, and her mother Tommo exemplify the challenges of this dietary approach. Minodi has been on this diet for 17 years, since the age of five, and it is expected to continue indefinitely. Her diet consists of specialized high-fat milk for cooking, with cooking oil added to soups to enhance fat absorption. Even simple treats are restricted; Minodi's dessert was limited to half a potato chip due to its carbohydrate content. Her mother expressed her hope that gene therapy could alleviate the burden of this restrictive diet, stating, "I can't do anything to make it delicious. I can't add sweet things. I think doctors have come up with the gene therapy because they are now aware that dietary therapy is tough on patients. I really appreciate that."

Challenges in Developing Treatments for Rare Diseases in Japan

Pediatricians at Gifu Medical University Hospital are also engaged in research for genetic treatments for other intractable diseases affecting approximately 340 children in Japan, many of whom have genetic origins. A significant hurdle in developing treatments for these rare conditions is the reluctance of pharmaceutical companies to invest in their production. These companies often deem such medicines unprofitable due to the small patient populations. This situation leads to frustration among medical professionals who possess the knowledge and methods to create these drugs but are unable to implement treatments.

Advocacy and Government Support

Doctors are actively advocating for government intervention to address these challenges. At a forum focused on advancing gene therapy, government officials acknowledged the time required to ensure safety before practical implementation of new treatments. While acknowledging that these therapies may not be immediately available, the government is providing support, including funding for basic research.

Furthermore, medical professionals emphasize the critical need to cultivate skilled personnel and foster venture capital investment to drive the development and accessibility of Japan-made medicines. The collective sentiment is a determination to collaborate between the government and medical staff to make these treatments available globally.

Conclusion and Future Outlook

The gene therapy clinical trial for GLUT1 deficiency syndrome represents a beacon of hope for patients and their families worldwide. While the full assessment of the therapy's safety and efficacy is ongoing, the trial signifies a crucial step towards potentially offering a more effective and less burdensome treatment option than the current dietary regimen. The broader implications of this research extend to other rare genetic diseases, underscoring the importance of continued investment in medical research, pharmaceutical development, and supportive government policies to bring life-changing treatments to those in need. Patients and their loved ones eagerly await the day when these advanced therapies become a reality.